Curated News
By: NewsRamp Editorial Staff
September 08, 2026
Nutriband Receives USPTO Notice for Trademarks on Abuse-Deterrent Fentanyl Patch
TLDR
- Nutriband's AVERSA fentanyl patch trademarks clear USPTO, protecting a market with $80-200M annual US sales potential.
- USPTO published Nutriband's trademarks, opening a 30-day opposition period before allowance issues for its AVERSA fentanyl patch.
- Nutriband's abuse-deterrent fentanyl patch aims to prevent misuse and accidental exposure, improving safety for patients and communities.
- Nutriband's AVERSA technology is patented in 46 countries, strengthening its global position against fentanyl abuse.
Impact - Why it Matters
This news matters because it marks a significant step forward for Nutriband in protecting its commercial brand for a product designed to combat the opioid crisis. The abuse-deterrent fentanyl patch has the potential to reduce opioid abuse, misuse, and accidental exposure, offering a safer alternative for patients who require potent pain management. Successful trademark registration could strengthen Nutriband's market position and revenue potential, impacting investors and public health outcomes.
Summary
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has received a Notice of Publication from the U.S. Patent and Trademark Office (USPTO) for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system. The trademarks will be published in the USPTO Trademark Official Gazette, and if no objections are filed during the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance. The fentanyl system incorporates Nutriband AVERSA™ abuse-deterrent transdermal technology and is being developed as a patch designed to deter abuse and misuse and reduce the risk of accidental exposure to transdermal fentanyl. Nutriband said the product has potential peak annual U.S. sales of $80 million to $200 million, while its AVERSA™ technology is protected by patents issued in 46 countries.
The company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product being the abuse-deterrent fentanyl patch incorporating AVERSA™ technology. This technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. Nutriband's website is www.nutriband.com. For the latest news and updates on NTRB, visit the company's newsroom at https://ibn.fm/NTRB.
InvestorWire, a specialized communications platform, distributed this press release. InvestorWire is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. The full press release can be found at https://ibn.fm/p1wVE. InvestorWire is based in Austin, Texas, and is powered by IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Receives USPTO Notice for Trademarks on Abuse-Deterrent Fentanyl Patch
